Grifols Therapeutics, Inc. Sustainability Profile
Grifols Therapeutics, Inc., a leading global biotechnology company, is headquartered in the United States and operates extensively across Europe, Latin America, and Asia. Founded in 1909, Grifols has established itself in the biopharmaceutical industry, specialising in the development of innovative therapies derived from human plasma. The company’s core products include immunoglobulins, albumin, and clotting factors, which are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. Grifols is renowned for its commitment to quality and safety, setting industry standards with its advanced manufacturing processes. With a strong market position, Grifols has achieved significant milestones, including the expansion of its global network of plasma collection centres. This strategic growth enhances its ability to deliver life-saving therapies to patients worldwide, solidifying its reputation as a trusted leader in the biopharmaceutical sector.
DitchCarbon Score
How does Grifols Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grifols Therapeutics, Inc.'s score of 75 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Grifols Therapeutics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Grifols, S.A., which cascades its emissions data and climate commitments down to Grifols Therapeutics. As part of its climate strategy, Grifols, S.A. has set various reduction targets, although specific details regarding these targets are not provided for Grifols Therapeutics. The company is involved in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are aimed at enhancing transparency and accountability in climate action. While no absolute emissions figures are reported, Grifols Therapeutics is committed to aligning with the broader sustainability goals of its parent company, Grifols, S.A., which focuses on reducing its carbon footprint and improving environmental performance across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 85,532,000 | 00,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 113,055,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 64,761,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 |
How Carbon Intensive is Grifols Therapeutics, Inc.'s Industry?
How Carbon Intensive is Grifols Therapeutics, Inc.'s Location?
Grifols Therapeutics, Inc.'s Scope 3 Categories Breakdown
Grifols Therapeutics, Inc.'s Scope 3 emissions, which increased by 11% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 53% of Scope 3 emissions.
Top Scope 3 Categories
Grifols Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Grifols Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
